In March 2024, a pivotal clinical trial was launched to evaluate what might well become the first new tuberculosis vaccine on the market in more than a century. As anticipation mounts for the trial to deliver results, Russell Rensburg argues that we need to start preparing for a rollout of the jab, but that we should think of preparation more widely than just the technicalities of regulatory approval and drug supply.
The United States National Institutes of Health has lifted its ban nearly 18 months after an order to stop work with South Africa. The funding ban created a crisis for HIV and TB research, including NIH grants and US Agency for International Development aid. Many of the world’s major advances over the past two decades in understanding the science of HIV arose from South African scientists and from studies conducted here, the vast majority of them funded by the NIH.
Bukhosi Mdletshe works as clinic manager at the Ensingweni clinic in in KwaZulu-Natal, and in his words, paying his dues to the rural community that raised him. Sue Segar and Thom Pierce spent some time with Mdletshe for Spotlight’s Rural Health Heroes series.
Soft toys, giggly kisses, and bright wards buzzing with excited children meet a driven team of staff and researchers producing world class work at Brooklyn Chest Hospital’s paediatric TB research hub. Biénne Huisman visits the wards and the Desmond Tutu TB Centre’s clinical site as it celebrates ten years and gets early insight of a cutting-edge new treatment trial.
The wins are there but the underlying reality remains, writes Professor Kogie Naidoo as she likens TB to a bridesmaid awaiting its turn to garner attention. The analogy is relevant given the overwhelming number of new TB infections and deaths each year globally for a disease persistently sitting in the shadow of other communicable and non-communicable diseases.
New TB tests have massive potential for South Africa’s struggle to get to grips with the age-old disease. Making the most of these new tests will require both ambition and smart implementation, argue Gaurang Tanna and Dr Yogan Pillay.
The persistence of TB is a reminder that medical solutions alone are not enough. Renier Coetzee and Ingrid Schoeman write that the disease thrives in conditions shaped by social injustice, including poverty, overcrowded housing, under-resourced health systems, and unequal access to care.
The only tuberculosis vaccine we have is a century old and offers only limited efficacy in children. With leading South African researchers involved in the pivotal clinical trials of three new tuberculosis vaccine candidates, we are on the verge of a major breakthrough, writes Associate Professor Angelique Kany Kany Luabeya.
The new government TB dashboard is a step forward for transparency and accountability in South Africa’s response to the ancient, but still deadly, disease. It is critical that we use it wisely to boost our testing efforts, argues a group of South Africa’s leading TB activists ahead of World TB Day on March 24th.
Spotlight has unveiled a new tuberculosis dashboard and graph generator. We hope this dashboard will help people get a clearer picture of the state of South Africa’s TB epidemic – an epidemic that still claims over 50 000 lives a year. It follows on the launch of a similar HIV dashboard last November.
South Africa had several “family chats” in which President Cyril Ramaphosa addressed the nation during the height of the COVID-19 pandemic. He should do the same for tuberculosis, argues Dr Janet Giddy of the advocacy group TB Proof.
The year’s biggest health story by far has been the cuts to US aid for health and US support for health research. But it’s also been a year of important HIV prevention developments, NHI court cases, ongoing crises in some of our provincial health departments, and some first steps toward accountability for the corruption at Tembisa Hospital.
